Prediction of locoregional extension and metastatic disease in prostate cancer: a review
暂无分享,去创建一个
[1] E. Metter,et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.
[2] D. Chan,et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.
[3] A. Partin,et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. , 1998, Critical reviews in clinical laboratory sciences.
[4] T. Piironen,et al. VARIOUS RATIOS OF HUMAN GLANDULAR KALLIKREIN (HK2) TO FREE AND TOTAL PSA IMPROVE DISCRIMINATION BETWEEN G1-G2 AND G3 PROSTATE TUMORS , 1999 .
[5] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[6] J. Muscat,et al. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer , 1996, Abdominal Imaging.
[7] A. Partin,et al. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.
[8] J. Oesterling,et al. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.
[9] J. Oesterling,et al. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.
[10] P. Narayan,et al. Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .
[11] P. Carroll,et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. , 1995, The Journal of urology.
[12] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[13] Srinivasan Vijayakumar,et al. Racial differences in prostate‐specific antigen levels in patients with local‐regional prostate cancer , 1992, The Prostate.
[14] D. Grignon,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. , 1995, Archives of pathology & laboratory medicine.
[15] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[16] D. Grignon,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995, Archives of pathology & laboratory medicine.
[17] Manyak Mj,et al. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998 .
[18] Hammond Eh,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995 .
[19] J. Oesterling,et al. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. , 1987, The Journal of urology.
[20] F. Freiha,et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. , 1994, Urology.
[21] A. Partin,et al. Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.
[22] R W Veltri,et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.
[23] M W Kattan,et al. Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.
[24] W. Catalona,et al. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.
[25] M. Kattan,et al. VALIDATION OF A NOMOGRAM FOR PREDICTING DISEASE RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER , 1999 .
[26] D Faraggi,et al. A neural network model for survival data. , 1995, Statistics in medicine.
[27] D. Bostwick,et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.
[28] O. Nilsson,et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.
[29] D. Bostwick,et al. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.
[30] P. Cuddy,et al. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. , 1996, International journal of radiation oncology, biology, physics.
[31] M. Manyak,et al. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998, Seminars in urologic oncology.
[32] A W Partin,et al. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. , 1998, Seminars in urologic oncology.
[33] ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS , 1999 .
[34] T. Reckwitz,et al. The use of percent free PSA for early detection of prostate cancer. , 1999, Journal of andrology.
[35] G G Klee,et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.
[36] A. Hanlon,et al. Analyzing predictive models following definitive radiotherapy for prostate carcinoma , 1997, Cancer.
[37] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[38] A. Tewari,et al. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. , 1998, The Journal of urology.
[39] K. Taari,et al. Magnetic resonance imaging of clinically localized prostatic cancer. , 1998, The Journal of urology.
[40] M. Kattan,et al. VALIDATION OF THE PARTIN TABLES FOR PREDICTING PATHOLOGIC STAGE OF CLINICALLY CONFINED PROSTATE CANCER , 1999 .
[41] A W Partin,et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.